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Ligation of lymphocyte function-associated antigen-1 on monocytes decreases
very late antigen-4–mediated adhesion through a reactive
oxygen species-dependent pathway
Kuo-Pin Chuang, Ya-Fang Huang, Yi-Ling Hsu, Hsiao-Sheng Liu, Hong-Chen Chen, and Chi-Chang Shieh
Monocyte-endothelial adhesion plays an
important role in monocyte trafficking
and hence is important for immune re-
sponses and pathogenesis of inflamma-
tory diseases including atherosclerosis.
The cross-talk between different inte-
grins on monocytes may be crucial for a
coordinated regulation of the cellular ad-
hesion during the complex process of
transendothelial migration. By using
monoclonal antibodies and recombinant
intercellular adhesion molecule 1 (ICAM-1)
to engage lymphocyte function-associ-
ated antigen 1 (LFA-1) on monocytic cells,
we found that the cellular adhesion to
vascular cell adhesion molecule 1
(VCAM-1) mediated by very late antigen 4
(VLA-4) was suppressed after this treat-
ment and the suppression depended on
the presence of reactive oxygen species
(ROSs). Inhibition of production of ROSs
through the use of inhibitor of the nicotin-
amide adenine dinucleotide phosphate
(NADPH) oxidase, but not inhibitors of
mitochondrial electron transport chain or
xanthine oxidase, revealed that this sup-
pression on VLA-4–mediated cellular
binding was mediated by ROSs produced
by phagocyte NADPH oxidase. Activation
of phosphoinositol-3 kinase and Akt ap-
pears to mediate this NADPH oxidase
activation through p47phox phosphoryla-
tion and Rac-1 activation. Our results
provide a novel pathway in which ROSs
play a critical role in integrin cross-talk
in monocytes. This signaling pathway
may be important for cellular transition
from firm arrest to diapedesis during
monocyte trafficking. (Blood. 2004;104:
4046-4053)
© 2004 by The American Society of Hematology
Introduction
Monocyte-endothelial adhesion and monocyte transendothelial
migration are important events in the immune surveillance and also
in pathogenesis of inflammatory diseases including atherosclerosis.
In physiologic conditions, circulating monocytes in various matura-
tion states enter tissue microenvironments and participate in the
immune responses through interacting with other leukocytes and
producing cytokines and reactive oxygen species (ROSs).1 In
response to atherogenic factors, monocytes in the bloodstream
attach, adhere, and spread on the luminal surface of vascular
endothelium. The cells then migrate across the endothelium and
accumulate within the intima and contribute to the formation of
atheroma.2,3
A panel of well-coordinated leukocyte adhesion molecules
including integrins, selectins, and immunoglobulin (Ig) superfam-
ily molecules is used to mediate the multistep process of leukocyte
recruitment to various tissues.4,5 How the adhesion activity of these
molecules is regulated has been the subject of intensive investiga-
tion in recent years. Monocytes express 1 and 2 integrins
including lymphocyte function-associated antigen 1 (LFA-1, L2
integrin) and very late antigen 4 (VLA-4, 41 integrin) on their
cell surface.6,7 The main ligands of LFA-1 include intercellular
adhesion molecule 1 (ICAM-1), ICAM-2, ICAM-3, junctional
adhesion molecule 1 (JAM-1), and fibrinogen,8,9 whereas ligands
of VLA-4 include vascular cell adhesion molecule 1 (VCAM-1)
and fibronectin.10 Binding of integrins to their respective ligands
induces outside-in signals that prepare cells for subsequent changes.
Outside-in signals by leukocyte integrins involve protein tyrosine
phosphorylation, cytoskeleton reorganization, and production of
ROSs.11 On the other hand, intracellular events change the
adhesiveness of integrins through molecular interactions at the
integrin cytoplasmic domains, known as inside-out signals.12,13
Differential regulation of the adhesion activity of integrins
through cytokines and cell-cell interaction contribute to flexibility
of the cell type-specific leukocyte adhesion in different microenvi-
ronments.14,15 Moreover, evidence indicates that on a given cell,
one subset of integrin may be regulated by ligation of another,16
hence confers the cell a temporally regulated order of adhesion to
different targets. Here, we investigated the interaction between
LFA-1 and VLA-4 integrins on monocytes and the potential
mechanisms underlying the ligand binding-induced regulation of
the integrin adhesion activity.
Materials and methods
Monoclonal antibodies
Mouse monoclonal antibodies (mAbs) against human p47phox, Rac-1, and
rabbit polyclonal antibodies for p47phox were purchased from Upstate
Biotechnology (Lake Placid, NY). Mouse anti-Akt and antiphospho-Akt
mAbs were purchased from Cell Signaling Technology (Beverly, MA).
From the Institute of Basic Medicine, Institute of Microbiology and Immunology,
and Department of Pediatrics, National Cheng-Kung University Medical
College, Tainan, Taiwan; and Institute of Biomedical Sciences, National Chung
Hsing University, Taichung, Taiwan.
Submitted May 14, 2004; accepted July 26, 2004. Prepublished online as
Blood First Edition Paper, August 12, 2004; DOI 10.1182/blood-2004-05-1822.
Supported by grants from the National Science Council, Taiwan (C.C.S.).
Reprints: Chi-Chang Shieh, Department of Pediatrics, National Cheng-Kung
University, 138 Sheng-Li Rd, Tainan 704, Taiwan; e-mail: cshieh@mail.
ncku.edu.tw.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 U.S.C. section 1734.
© 2004 by The American Society of Hematology
4046 BLOOD, 15 DECEMBER 2004  VOLUME 104, NUMBER 13
For personal use only.on June 20, 2016. by guest  www.bloodjournal.orgFrom 
Antiphospho-serine mAb was from Sigma (Saint Louis, MO). Anti-VLA-4
antibody (HP2/1) and horseradish peroxidase (HRP)–conjugated rabbit
antimouse IgG were from Immunotech (Marseille, France). Ligand-induced
binding site-specific VLA-4 antibody (HUTS-4) was from Chemicon
(Temecula, CA). An irrelevant mouse mAb (clone 1-64.1) was a gift from
Dr Y. S. Lin (Institute of Microbiology and Immunology, National
Cheng-Kung University Medical College, Tainan, Taiwan). Fluorescein
isothiocyanate (FITC)–conjugated donkey antihuman IgG was from Bender
MedSystems (Burlingame, CA). FITC-conjugated rabbit antimouse IgG
was from ICN Biomedical (Aurora, OH).
Cell culture
U937 cells (American Type Culture Collection, Manassas, VA, [ATCC]
CRL-1593.2) were cultured in RPMI 1640 medium (Gibco, Grand Island,
NY) supplemented with 2 mM L-glutamine, 10% heat-inactivated fetal
bovine serum (FBS; Hyclone, Logan, UT), and 40 U/mL penicillin/
streptomycin (Gibco).
Recombinant protein-coated beads
Protein G beads (200 L; Amersham Biosciences, Uppsala, Sweden) were
washed twice in phosphate-buffered saline (PBS) and resuspended in
adhesion buffer, pH 7. ICAM-1-FC and FC recombinant proteins, which
respectively contain extracellular domains of human ICAM-1 and Fc
portion of human IgG1 and Fc portion alone,17 were added to final
concentrations of 50 to 500 g/mL. The beads were rotated at 4°C for 14
hours in adhesion buffer and blocked with 0.1% bovine serum albumin
(BSA) for 2 hours at room temperature. The beads were then washed twice
in adhesion buffer for use in the following adhesion experiments.
Adhesion assay
Cell-to-protein adhesion assays were performed as previously reported.18
Briefly, bottoms of 96-well plates were coated overnight at 4°C with 30
g/mL recombinant VCAM-1-FC (produced by transfected Chinese ham-
ster ovary [CHO] cells, containing the first 3 N-terminal immunoglobulin
domains of human VCAM-1 and the Fc portion of human IgG118),
fibronectin (2 g/mL), laminin (2 g/mL; Gibco), vitronectin (2 g/mL;
Sigma), or FC in a coating buffer (15 mM sodium carbonate, 35 mM
sodium bicarbonate; pH 9.6). After washing with PBS, the wells were
blocked with 0.1% BSA. U937 cells were labeled with 12.5 g/mL 2,
7-bis-(2-carboxyethyl)-5 (and -6) carboxyfluorescein (BCECF-AM; Molecu-
lar Probes, Eugene, OR) for 30 minutes at 37°C. After being washed with
PBS, 5  104 labeled U937 cells were resuspended in 1.2 mL adhesion
buffer (137 mM NaCl, 3 mM KCl, 20 mM 4-(2-hydroxyethyl)piperazine-1-
ethane sulfonic acid [HEPES, Hyclone], and 1 mM CaCl2, pH 7.4) with or
without diphenylene iodonium (DPI), catalase, N-acetyl cysteine (NAC),
rotenone, or allopurinol (all purchased from Sigma) for 15 minutes. The
cells were then treated with irrelevant antibody, TS1-18, TS1-22, or protein
G-ICAM-1-FC or protein G-FC beads for 1 hour at 37°C and incubated in
wells at 37°C for 15 minutes. Unbound cells were washed from the plates
with adhesion buffer (3 or 4 washes). Bound cells were detected using a
fluorescence plate reader (HTS7000 Bioassay Reader; Perkin Elmer,
Norwalk, CT) and read as fluorescence units. Cell viability, measured by
flow cytometry with the staining of annexin V-FITC (BD PharMingen, Palo
Alto, CA), was not changed with LFA-1 ligation in conditions used in the
adhesion assays. No cell aggregation or apparent changes in cell morphol-
ogy were observed with light microscopy or flow cytometric analysis after
the LFA-1 ligation (not shown).
Cell surface staining with mAbs
U937 cells were stained with primary antibodies. After 3 washes, these cells
were then stained with a FITC-conjugated secondary antibody against
mouse immunoglobulin (ICN Biomedical) and analyzed on an Epics
XL/MCL flow cytometer (Beckman-Coulter, Miami, FL). The cell staining
experiments were performed at 4°C using buffer of PBS (pH 7.4)
containing 1% BSA (Sigma).
Detection of ROSs
ROSs were measured using a 2,7-dichlorodihydrofluorescein diacetate
(H2DCF-DA; Molecular Probes) fluorescent method. H2DCF-DA (5 M)
was added to 6  105 U937 cells in adhesion buffer with or without DPI,
allopurinol, rotenone (Sigma), LY29002 (Calbiochem, San Diego, CA), Akt
inhibitor (Calbiochem), and U0126 (Calbiochem) for 15 minutes, then
treated with anti-LFA-1 antibody and incubated at 37°C for 1 hour. The
fluorescence was then detected at the indicated time using a fluorescence
plate reader at excitation/emission of 475/525 nm (HTS7000 Bioassay
Reader; Perkin Elmer).
Immunoprecipitation and Western blot analysis
U937 cells (1  107) were incubated in adhesion buffer in the presence or
absence of stimuli for the indicated times at 37°C. Where indicated, cells
were preincubated with the pharmacologic inhibitor LY294002 (20 M) for
15 minutes. The reactions were stopped by placing the cells on ice and then
centrifuging at 300g for 5 minutes. The cell pellets were lysed with 600 L
lysis buffer (containing Tris-buffered saline [TBS], pH 7.6, 1% Triton
X-100 [TX100], 1 mM phenylmethylsulfonyl fluoride [PMSF], and com-
plete protein inhibitor cocktail [Boehringer Mannheim, Mannheim, Ger-
many]) by shaking for 30 minutes at 4°C. The cell lysates were then
centrifuged at 17 500g for 15 minutes at 4°C. For immunoprecipitation, the
lysates were immediately incubated with polyclonal anti-p47phox antibody
(1 g/L  107 cells; Upstate Biotechnology) overnight at 4°C. Sepharose-
protein G beads (Amersham Biosciences) were added to the lysates (50 L
beads/600 L lysate), and the mixture was incubated overnight at 4°C with
constant rocking. The protein G beads were washed 3 times in lysis buffer
and boiled in sodium dodecyl sulfate (SDS) sample buffer (TBS with 10%
glycerol, 3% SDS, and 100 mM dithiothreitol [DTT]), and the proteins were
resolved on 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
For Akt Western blotting experiments, lysates prepared from 1  106 cells
were used for each analysis on 12% SDS-PAGE. For Western blotting
analysis, proteins were electroblotted to polyvinylidene difluoride (PVDF)
membranes (Millipore, Bedford, MA). The membranes were incubated
with 5% nonfat dry milk in TBST (Tween 20 0.2%, NaCl 0.1 M, Tris base,
20 mM, pH 7.6) overnight at 4°C to reduce any nonspecific binding,
followed by incubation with the primary antibody, anti-Akt (Cell Signaling
Technology) antiphospho-Akt (Cell Signaling Technology), anti-p47phox
mAb (Upstate Biotechnology), or antiphospho-serine mAb (Sigma) diluted
1:2000 in 5% nonfat dry milk in TBST. After washing several times with
TBST, the membranes were incubated for 1 hour with 0.1 g/mL
HRP-conjugated goat antimouse IgG (ICN Biomedical) in 5% nonfat dry
milk in TBST and were washed several times. The blot was then visualized
with a chemiluminescent substrate (enhanced chemiluminescence [ECL];
Amersham Biosciences) and then exposed to autoradiography films (Fuji,
Tokyo, Japan).
Determination of VLA-4 activation state with recombinant
soluble VCAM-1
U937 cells (6  105) were resuspended in adhesion buffer. The VCAM-
1-FC and FC fusion proteins were added at 10 g/mL and incubated for 30
minutes at 37°C. After incubation, cells were washed twice in adhesion
buffer and resuspended in the same buffer containing FITC-conjugated
donkey antihuman IgG at a 1:100 dilution (Bender MedSystems). After a
30-minute incubation at 4°C, cells were washed twice and bound antibody
was detected using a flow cytometer (Beckman-Coulter).
Determination of active Rac with the “pull-down” assay
The Escherichia coli-expressing GST protein fused to human PAK was
kindly provided by Dr J. G. Collard (Netherlands Cancer Institute, Utrecht,
the Netherlands). Bacteria were grown to OD600  0.6 at 37°C and then
induced with 1 mM isopropylthiogalactoside (IPTG) for 3 hours at 37°C.
Bacteria were then pelleted, washed, and resuspended in 1% TX100
containing 1 mM PMSF, 1 mM MgCl2, and 1 mM DTT, and incubated on
ice for 30 minutes. The bacteria were then sonicated at 0°C for three
1-minute intervals at a setting of 7 with an Ultrasonic Processor XL
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(Misonix, Farmingdale, NY). Insoluble material was removed by centrifu-
gation at 15 000g. One hundred microliters of glutathione-S-Sepharose 4B
beads (Amersham Pharmacia Biotech) was added to the cleared lysate,
incubated for 30 minutes at 37°C, and washed 3 times in 1% TX100. The
GST-PAK beads were then added to cleared U937 cells lysates from
1  107 cells at 4°C. After 1 hour, the beads were collected by centrifuga-
tion and washed 3 times in 25 mM Tris-HCl, pH 7.5, 1% TX100, 100 mM
NaCl, and 30 mM MgCl2. The beads were then resuspended in sample
buffer and boiled under reducing conditions for 10 minutes. The precipi-
tated proteins and equal amount of cell lysates were resolved with 12%
SDS-PAGE and transferred to PVDF membranes. Membranes were incu-
bated with 5% nonfat dry milk in TBST overnight at 4°C to reduce any
nonspecific binding and followed by incubation for 1 hour with primary
antibody (0.3 g/mL anti-Rac1 mAb; Upstate Biotechnology). After
washing several times with TBST, the membranes were incubated for 1
hour with 0.1 g/mL HRP-conjugated goat antimouse IgG in 5% nonfat dry
milk in TBST and washed several times. The blot was then visualized with a
chemiluminescent substrate (ECL; Amersham Biosciences) and then ex-
posed to autoradiography film (Fuji, Tokyo, Japan).
Results
Ligation of LFA-1 on U937 cells decreases cellular
binding to VCAM-1
To determine the effects of LFA-1 ligation on the function of 1
integrin-mediated cellular binding, we used a human monocytic
cell line, U937, in a static-state adhesion assay. U937 cells were
treated with anti-LFA-1 antibodies or a recombinant ICAM-1
immobilized on Sepharose beads and then tested for their ability to
bind to VCAM-1 recombinant protein-coated plates after 1 hour of
treatment. VCAM-1 binding of U937 cells treated with anti-LFA-1
mAbs, TS 1-18 (Figure 1A) and TS1-22 (Figure 1B), significantly
decreased to about 60% of the original level in a dose-responsive
manner when compared with cells treated with control antibodies.
A similar effect was observed when the natural ligand of LFA-1,
ICAM-1, was used to treat the cells. Although treatment of cells
with uncoated beads and beads coated with FC protein showed no
effects, treatment with ICAM-1-FC–coated beads decreased cellu-
lar binding to VCAM-1 to a comparable degree (Figure 1C).
Ligation of U937 cells to ICAM-1 decreases the expression of
VLA-4 with activated conformation
To elucidate the molecular changes that cause the decrease in
cellular adhesion to VCAM-1, we treated U937 cells with a
recombinant ICAM-1 for 1 hour and then analyzed the expression
of total VLA-4 and its ligand-induced activated epitope, which
indicates activated VLA-4 integrin on the cell surface. For U937
cells treated or not treated with the recombinant ICAM-1, the
expression levels of total VLA-4 integrin were not changed (Figure
2A). However, the level of activated VLA-4 on treated U937 cells
decreased with increasing concentrations of ICAM-1 (Figure 2B).
We then used flow cytometry to measure the soluble VCAM-1
binding of U937 cells after LFA-1 ligation with TS1-18 mAb. A
significant decrease in VCAM-1 binding, which represents sup-
pressed levels of activated VLA-4, was observed in cells stimulated
with an increasing concentration of anti-LFA-1 mAb (Figure 2C).
LFA-1 ligation-induced decrease in VCAM-1 adhesion
is inhibited by antioxidants
We previously reported that ROSs, including superoxide and
hydrogen peroxide, affect integrin-mediated leukocyte adhesion.18
We hence tested whether stimulation of the U937 cells with
Figure 1. Ligation of LFA-1 on U937 cells decreased cellular binding to VCAM-1. Adhesion assay experiments for U937 cells binding to VCAM-1-FC and FC recombinant
proteins were performed in the absence or presence of different concentrations of TS1-18 (A), TS1-22 (B), or immobilized ICAM-1-FC (C). The experiments were performed
with 8 replicates and were repeated 3 times with similar results. Data are expressed as mean  SD and analyzed with 2-tailed Student t test. Results showing significant
differences in cellular binding in the presence of LFA-1 ligation treatments in comparison with their respective controls (isotype-matched mAb for panels A and B and
immobilized FC for panel C) are marked with ** for P  .005 or * for P  .05. ICAM indicates the ICAM-1-FC recombinant protein in the figures.
Figure 2. Ligation of LFA-1 on U937 cells decreased the expression of VLA-4
with activated conformation. U937 cells were cultured with plain medium (black
profile) or treated with 500 ng/mL, 250 ng/mL, or 50 ng/mL soluble ICAM-1-FC, and
500 ng/mL soluble FC protein or Mn2	 (1 mM) and then stained with (A) a
conformation-independent anti-VLA-4 antibody (HP1/2) or (B) a ligand-induced
binding site-specific VLA-4 antibody (HUTS-4). U937 cells were then analyzed with
flow cytometry. The mean fluorescence intensities (MFIs) of the ligand-induced
binding site-specific antibody staining for Mn2	, 500 ng/mL FC, 50, 250, and 500
ng/mL ICAM-1-FC–treated cells are 61.51, 46.81, 19.94, 14.78, and 12.52, respec-
tively. (C) U937 cells were cultured with plain medium (black profile) or treated with 50
ng/mL, 100 ng/mL, or 200 ng/mL TS1-18, and 200 ng/mL isotype-matched control
mAb or Mn2	 (1 mM) and then incubated with VCAM-1-FC protein and a FITC-
labeled anti-FC antibody. U937 cells were then analyzed with flow cytometry. The
MFIs of the VCAM-1-FC protein binding for Mn2	 and 50, 100, or 200 ng/mL
TS1-18–treated cells are 34.30, 20.33, 15.62, 9.67, and 8.78, respectively. This
experiment was repeated 3 times with similar results.
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anti-LFA-1 antibody increased the production of ROSs. After the
cells were stimulated with anti-LFA-1 mAb, cellular production of
ROSs by U937 cells increased and reached a plateau after 50
minutes of antibody treatment (Figure 3A), whereas treatment with
an isotype-matched antibody did not significantly alter cellular
production of ROSs. We also tested the production of ROSs in
U937 cells after different concentrations of anti-LFA mAb treat-
ment. We found that there was a dose-responsive increase in ROSs
in the range of 50 to 300 ng/mL anti-LFA-1 and the production of
ROSs plateaued after 200 ng/mL (Figure 3B). We hence used 200
ng/mL anti-LFA-1 for 60 minutes in the following experiments.
To determine whether this LFA-1 ligation-induced produc-
tion of ROSs leads to decreased cellular binding to VCAM-1,
we tested the effects of catalase on cellular binding after LFA-1
ligation. We found that the decrease of U937 cell binding to
VCAM-1 after LFA-1 ligation, either by anti-LFA antibodies or
by a recombinant ICAM-1, was reversed by catalase treatment
(Figure 3C). A similar reversal of the suppression of cellular
binding was observed when the cells were treated with NAC, a
scavenger of the hydrogen peroxide (Figure 3D). We performed
adhesion experiments to clarify the specificity of the LFA-1–
induced suppression of cellular adhesion by using other extracel-
lular matrix protein ligands (fibronectin, laminin, and vitronec-
tin) of monocyte integrins as the fixed proteins. We found that
the LFA-1 ligation-induced decrease in cellular binding was
found in experiments using VCAM-1 and fibronectin, which are
known ligands for VLA-4 integrin, whereas the cellular binding
to laminin (ligand for 11, 21, 31, and 61 on
monocytes) and vitronectin (ligand for v3), was not affected
by LFA-1 ligation. Moreover, U937 cell binding to vitronectin
and laminin, different from the binding to VCAM-1 and
fibronectin, was not affected by the presence of catalase (Figure
3E). These results suggest that LFA-1 ligation-induced suppres-
sion of integrin adhesion is limited to VLA-4 integrin. The
effects of catalase and NAC on VLA-4–mediated adhesion were
also examined with cell surface analysis of activated VLA-4.
The presence of catalase restored the expression of activated
VLA-4 on U937 cells treated with the recombinant ICAM-1
(Figure 4A) or anti-LFA-1 antibody (Figure 4B) detected with
conformation-dependent mAb or soluble recombinant VCAM-1,
respectively. These findings indicate that the ROSs produced by
leukocytes after LFA-1 ligation are essential for the suppression
of cellular binding to VCAM-1.
ROSs produced by NADPH oxidase are modulators
of cell adhesion
To clarify the origin of the production of ROSs during integrin-
mediated cell adhesion, the U937 cells were pretreated with DPI
(inhibitor of NADPH oxidase), allopurinol (inhibitor of xanthine
oxidase), and rotenone (inhibitor of mitochondria) before seeding
them onto VCAM-1-FC–coated wells for adhesion assays. DPI
pretreatment of U937 cells reversed the inhibitory effect of LFA-1
ligation on cellular binding to VCAM-1 (Figure 5A). In contrast,
pretreatment of U937 cells with rotenone and allopurinol caused no
apparent changes on cellular adhesion to VCAM-1 (Figure 5B-C).
To directly investigate the change of production of ROSs by U937
cells after inhibitor treatment, we measured the production of ROSs
with or without LFA-1 ligation. We found that both DPI and
Figure 3. LFA-1 ligation induced U937 cells to pro-
duce ROSs that may modulate VCAM-1 binding.
U937 cells were labeled with H2DCF-DA in the presence
or absence of anti–LFA-1 antibody and the production of
ROSs was measured by fluorescence intensity. After
LFA-1 ligation, the production of ROSs increased in a
time-dependent (A) and dose-dependent (B) manner.
Adhesion experiments were then performed in the pres-
ence or absence of TS1-18, TS1-22, or immobilized
ICAM-1-FC in the presence or absence of (C) catalase
(0.3 U/L) or (D) NAC (10 M). Cellular binding to
fibronectin, laminin, or vitronectin in the presence or
absence of catalase was compared with the binding to
VCAM-1-FC (E). The experiments in panels A-B were
performed with 4 replicates and repeated 3 times with
similar results. The experiments in panels C-E were
performed with 8 replicates and were repeated 3 times
with similar results. Data are expressed as mean  SD
and analyzed with 2-tailed Student t test. Results show-
ing significant differences when compared with the base-
line fluorescence are marked with ** for P  .005 or * for
P  .05.
Figure 4. Catalase reversed the suppressive effects of LFA-1 ligation on VLA-4
activation. The effects of catalase on VLA-4–mediated adhesion were examined
with cell surface analysis of activated VLA-4. U937 cells were treated with (A) 500
g/mL ICAM-1-FC protein and (B) 200 ng/mL TS1-18 antibody in the presence or
absence of catalase (0.3 U/L) and then stained with (A) a ligand-induced binding
site-specific VLA-4 antibody (HUTS-4) or (B) the soluble VCAM-1 protein. U937 cells
were then analyzed with flow cytometry. The MFIs of the ligand-induced binding
site-specific antibody staining for control FC, ICAM-1-FC, and ICAM-1-FC plus
catalase-treated cells are 46.81, 12.52, and 46.67 respectively (A). The MFIs of the
VCAM-1-FC protein binding for isotype control antibody-treated, TS1-18 plus
catalase-treated, and TS1-18–treated cells are 20.33, 8.78, and 15.58, respectively
(B). This experiment was repeated twice with similar results.
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rotenone, but not allopurinol, significantly suppressed levels of
ROSs in baseline conditions. After LFA-1 ligation with TS1-18
mAb, DPI-treated U937 cells showed no increase in ROSs,
whereas allopurinol- and rotenone-treated cells produced increased
levels of ROSs (Figure 5D). These results suggested that increased
production of ROSs by NADPH oxidase contributes to the
suppression of VCAM-1 binding in U937 cells.
Inhibition of PI3K activity selectively blocks LFA-1
ligation-induced production of ROSs
Phosphoinositol-3 kinase (PI3K)–Akt and ERK1/2 are reported to
be involved in NADPH oxidase activation by phosphorylating
serine residues on p47phox in neutrophils.19-21 To unravel the
signaling leading to LFA-1 ligation-stimulated production of ROSs
in U937 cells, we investigated the effects of PI3K inhibitor,
LY294002, and ERK1/2 inhibitor, U0126, on cellular production of
ROSs. U937 cells preincubated with LY294002 or Akt inhibitor did
not have increases in production of ROSs induced by ICAM-1
ligation, while U0126 had no significant effects (Figure 6).
PI3K-Akt thus may have an essential role in the intracellular
signaling leading to NADPH oxidase activation.
LFA-1 ligation regulates Akt phosphorylation via a
PI3K-dependent pathway
To understand the mechanisms of how LFA-1 ligation induced
production of ROSs through PI3K, we examined the effect of
LFA-1–binding TS1-18 and TS1-22 mAbs on Akt phosphorylation
at 10- minute intervals. Both mAbs induced Akt phosphorylation in
a time-dependent manner and plateaued 50 minutes after the
stimulation. Preincubation of PI3K inhibitor LY294002 signifi-
cantly decreased Akt phosphorylation (Figure 7A). These results
strongly suggest the involvement of PI3K and Akt in LFA-1
ligation-induced ROS production.
LFA-1 ligation enhances p47phox phosphorylation and Rac-1
activation via a PI3K-dependent pathway
Phosphorylation of the cytosolic oxidase subunit p47phox is a key
event in NADPH oxidase activation. We therefore tested the
phosphorylation state of the p47phox after LFA-1 ligation. We
found that p47phox phosphorylation increased 60 minutes after
TS1-18 stimulation in U937 cells. However, for cells pretreated for
15 minutes with the PI3K inhibitor LY294002, the increase in
p47phox phosphorylation was reversed (Figure 7B).
The small guanosine triphosphatase (GTPase) Rac-1 is a major
regulator for the NADPH oxidase activity in macrophages.22 We
thus explored whether the activity of this small GTPase in U937
monocytic cells is altered following LFA-1 ligation. “Pull-down”
assays using the fusion protein GST-PAK, a Rac-binding domain of
the PAK effector molecule that only binds the active GTP-bound-
Rac, were performed to detect changes in the activity of Rac-1 in
U937 cells after LFA-1 ligation. An increase in the activity of
Rac-1 is consistently observed 60 minutes following the LFA-1
ligation. Similar to the p47phox phosphorylation, the increase of
Rac-1 activation was inhibited by LY294002 pretreatment (Figure
7C). These results suggest that the PI3K pathway participates in the
LFA-1–induced phosphorylation of p47phox and Rac-1 activation
and leads to the activation of NADPH oxidase.
Discussion
To be recruited to inflammatory tissues, leukocytes express differ-
ent integrins to adhere to a variety of vascular or tissues ligands.5,23
Integrins are heterodimeric proteins expressed on the cell surface.
In addition to acting as “cellular glue,” integrins communicate
biochemical or mechanical signals across the plasma membrane to
influence cellular functions.13,24 Moreover, integrins may adopt
active or inactive conformations to determine their adhesiveness in
response to cellular signals.25 When more than one species of
Figure 6. Inhibition of PI3K activity selectively blocked LFA-1 ligation-induced
production of ROSs. U937 cells (6  105 cells for each condition) were preincu-
bated with LY294002 (20 M), Akt inhibitor, and U0126 (30 M) for 15 minutes, then
labeled with H2DCF-DA and stimulated with anti–LFA-1 antibody. Increase of
production of ROSs was measured as increase in fluorescence intensity after 1 hour.
These experiments were performed with 4 replicates and were repeated 3 times with
similar results. Results showing significance difference in fluorescence intensity in
comparison with baseline levels are marked with ** for P  .005 or * for P  .05.
Figure 5. Ligation of LFA-1 decreased cellular ad-
hesion to VCAM-1 through a NADPH oxidase–
dependent pathway. U937 cells were labeled with
BCECF-AM in the absence or presence of (A) DPI (5 M),
(B) rotenone (10 M) or (C) allopurinol (4 M) and then
treated with anti–LFA-1 mAb TS1-18 and tested for
binding to the recombinant VCAM-1-FC and FC. (D) After
LFA-1 ligation with TS1-18 mAb, DPI-, allopurinol-, and
rotenone-treated U937 cells were measured for their
increase in production of ROSs with H2DCFDA fluores-
cence. The experiments were performed with 8 replicates
and were repeated 3 times with similar results. Results
showing significant differences in the comparison with
negative controls are marked with ** for P  .005 and *
for P  .05. Data are expressed as mean SD.
4050 CHUANG et al BLOOD, 15 DECEMBER 2004  VOLUME 104, NUMBER 13
For personal use only.on June 20, 2016. by guest  www.bloodjournal.orgFrom 
integrins are expressed on leukocyte cell surface, cross-talk be-
tween these integrins may provide the orderly activation of cellular
adhesion molecules necessary for different stages of cellular
trafficking.16,26,27 This study was undertaken to examine the
functional interaction on monocytic cells between LFA-1 and the
VLA-4 integrins when LFA-1 is ligated. We used specific anti-
LFA-1 mAbs or a recombinant ICAM-1 protein for ligation of
LFA-1 and measured the cellular binding to a recombinant
VCAM-1 protein and the conformational changes on VLA-4
integrin on monocytic cells. We found that the ligation of mono-
cytic LFA-1 by ICAM-1 or its specific mAbs leads to a significant
decrease in binding of 41 to VCAM-1. This inhibitory effect
was mediated by a PI3K-dependent pathway that leads to the
activation of NADPH oxidase and production of ROSs.
Once in contact with endothelium in postcapillary venules,
monocytes begin rolling on the luminal surface of endothelium
through a mechanism involving selectins as well as integrins.28
Engagement of VLA-4 by its endothelial ligand, VCAM-1, appears
to stimulate subsequent leukocyte migration, which requires LFA-
1.29 VLA-4 (41) thus appears to be important in the early steps
of tethering, rolling, and firm arrest, whereas LFA-1 (L2) is
involved in the process of firm arrest and cell flattening of
monocytes.1,30 These monocytes then pass through the border of
endothelial cells in a process named diapedesis or transendothelial
migration. In the transition from firm arrest to diapedesis, mono-
cytes move from the luminal endothelial cell surface to the cell
junctions, where the distribution of integrin ligands is different. A
novel molecule, JAM-1, was recently found to be a counterreceptor
for LFA-1 and involved in transendothelial migration of T cells and
neutrophils.9 This immunoglobulin superfamily adhesion molecule
expressed on endothelial cells is redistributed from tight junction to
luminal plasma membrane after treatment with proinflamma-
tory cytokines, presumably to guide leukocytes through the
transmigration.
During the process of leukocyte transendothelial migration,
both endothelial cells and leukocytes need to send signals intracel-
lularly to accommodate this complex cellular interaction involving
cellular adhesion and detachment between different cell types.
Transmigration induces within the endothelial cells a transient
increase in intracellular calcium, which can activate myosin
light-chain kinase and facilitate leukocyte passage.31,32 On the
leukocyte side, the activation of NADPH oxidase induced by the
ligation of LFA-1, which should remain ligated with ICAM-1
and JAM-1 during the transmigration process, may be one of the
key signals for the leukocytes to be released from the luminal
plasma membrane and continue the migration to the endothelial
cell junction.
Phagocyte NADPH oxidase, an enzyme complex made up of
membrane-bound gp91phox and p22phox, and cytoplasmic
p47phox, p67phox, and p40phox, and the small GTPase Rac1/2, is
the major source of ROSs in leukocytes.33 Gene mutations leading
to defective production of ROSs in NADPH oxidase cause a severe
congenital immunodeficiency named chronic granulomatous dis-
ease.34,35 This enzyme has been implicated in the inflammatory
process of atherosclerosis in both humans and in animal mod-
els.36-38 Recently, polymorphism in NADPH oxidase genes was
reported to be among the significant predictors for the risk of
myocardial infarction in humans.39 The understanding of the
mechanisms regulating NADPH oxidase during monocyte traffick-
ing thus is relevant to the inflammatory pathogenesis of
atherosclerosis.
It has been shown that activation of Rac-1/2 and phosphoryla-
tion of p47phox are important steps in turning on NADPH oxidase
by bringing the cytoplasmic components to the membrane-bound
components and form a complete enzyme complex.22,40-42 Recently,
Sanchez-Martin et al reported that LFA-1 ligation in T cells induces
a transient activation of Rac-1 that is regulated by PI3K/Akt-1.43
That finding is contrary to the result of a previous report showing
that integrin-mediated cellular adhesion to extracellular matrix
(ECM) proteins transiently suppresses the generation of ROSs due
to inhibition of Rac-2 activation in human neutrophils.44 Different
from neutrophils, monocytes were reported to use Rac-1, but not
Rac-2, as a component of the activated NADPH oxidase.45 In this
study, we were not able to detect Rac-2 protein activation in our
monocytic cells used in the experiments (data not shown). The
regulation of NADPH oxidase after integrin ligation thus may be
different in monocytes and neutrophils regarding the regulation by
Rac activation. Our results that LFA-1 ligation on monocytic cells
leads to significant phosphorylation of p47phox and activation of
Rac-1 implicate that these changes are responsible for the increased
production of ROSs by NADPH oxides. These results are in
accordance with previous reports showing that activation of the
NADPH oxidase requires a 2 integrin-induced targeting of the
Rac as well as phosphorylated p47phox and p67phox to the plasma
membrane in neutrophils.46
Figure 7. LFA-1 ligation induced Akt phosphorylation, p47 phox phosphorylation, and Rac-1 activation via a PI3K-dependent pathway. (A) U937 cells (1  106 cells
for each condition) were preincubated with or without LY294002 (20 M) and stimulated with TS1-18 and TS1-22 for the indicated time periods. The cell lysates were subjected
to Western blot analysis using phospho-Akt antibody or Akt antibody to determine the activated and the total amount of the Akt protein. (B) U937 cells were pretreated with or
without the PI3K inhibitor LY294002 (20 M) for 15 minutes and stimulated with TS1-18 for 1 hour. The cell lysates were immunoprecipitated with rabbit anti-p47phox polyclonal
antibody. The precipitants were then resolved with SDS-PAGE and subjected to Western blot analysis using antiphospho-serine antibody or a mouse anti-p47phox mAb.
(C) After TS1-18 stimulation, cells were lysed and the Rac-1–activated fraction (Rac-1-GTP) was precipitated with GST-PAK beads. Aliquots of lysates were analyzed along
with the precipitates by Western blotting using an anti-Rac-1 mAb. These experiments were repeated 3 times with similar results.
LFA-1 BINDING REDUCES VLA-4 ADHESION THROUGH ROSs 4051BLOOD, 15 DECEMBER 2004  VOLUME 104, NUMBER 13
For personal use only.on June 20, 2016. by guest  www.bloodjournal.orgFrom 
Integrin ligation on leukocytes initiates multiple signal transduc-
tion pathways through molecular interaction between integrin
cytoplasmic domains and intracellular signaling proteins.24 Among
the integrin-initiated signaling pathways, Akt and Erk have been
reported to mediate the activation of NADPH oxidase through
protein phosphorylation in neutrophils.20,21 Recent reports showed
that Akt, which is activated by PI3K, phosphorylates the serine
residues on p47phox and led to the N-formyl-methyonyl-leucyl-
phenylalanine (fMLP)–induced respiratory burst in neutrophils.20
Our results showing that PI3K inhibition suppresses the LFA-1
ligation-induced NADPH oxidase activation while Erk inhibition
did not have apparent effects strongly suggest that PI3K-Akt
pathway has a major role in the LFA-1 ligation-induced ROS-
mediated signaling in monocytic cells.
The role of ROSs as mediators of cellular signaling has been
shown in many cell types.47-49 Our previous investigation demon-
strated that granulocyte-generated ROSs modulate eosinophil bind-
ing and may affect the development of allergic inflammation.18
Production of ROSs by leukocyte NADPH oxidase has been
reported to modulate the expression of adhesion molecules includ-
ing VCAM-1 and ICAM-1.50,51 Moreover, ROSs are implicated in
regulating cell adhesion by affecting protein tyrosine phosphoryla-
tion involved in integrin signaling.52 ROSs may also directly affect
the redox states and hence the molecular conformations of VLA-4
integrin and lead to changes in their adhesion activity.53 Because
the ROSs generated by NADPH oxidase may be released either
inside or outside the cells, the ROSs may modify their intracellular
or extracellular targets to modulate the cellular adhesion. Based on
our finding that catalase, which should act extracellularly in our
experiments, reverses the LFA-1–ligation induced VCAM-1 bind-
ing (Figure 3C), we surmise that intracellular ROSs diffusing
through the plasma member to extracellular space may be essential
for regulating VCAM-1 binding. Even though both the mitochon-
dria inhibitor, rotenone, and the NADPH oxidase inhibitor, DPI,
reduced the levels of production of ROSs in U937 cells, only DPI,
which suppresses the LFA-1–induced increase in ROSs, inhibits
cellular binding to VCAM-1 (Figure 5). This suggests that both the
absolute concentration and the temporal changes in levels of ROSs
may be important for the modulation of integrin-mediated cellular
binding in U937 cells. The precise mechanisms through which
NADPH oxidase-generated ROSs suppress the activity of VLA-4
in monocytic cells requires further investigation.
In conclusion, the dynamic interaction between integrins on mono-
cytic cells through a bidirectional signaling process may be a key event
in determining the transition from firm arrest to diapedesis in leukocyte
trafficking. Our finding that ligation of LFA-1 on a monocytic cell line
leads to deactivation of VLA-4 in an ROS-dependent manner reveals a
novel role of phagocyte NADPH oxidase in monocyte diapedesis. With
the critical role of monocytic cell trafficking in antigen presentation and
pathogenesis in vascular diseases, our current results not only shed light
on a crucial signaling pathway for the leukocyte transendothelial
migration but also provide potential therapeutic targets that can be
modulated by drugs modifying phagocyte NADPH oxidase activity.54
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